Key facts
- This page summarizes Sarah O'Brien's Form 4 filing for Provention Bio, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 11 Jan 2023, 20:13.
Sarah O'Brien - 10 Jan 2023 Form 4 Insider Report for Provention Bio, Inc.
- Reporting relationship
- Chief People Officer
- Issuer ticker
- N/A
- Reported as of
- 10 Jan 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 11 Jan 2023, 20:13:50 UTC
- Prior SEC filing
- 19 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thierry Chauche, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sarah O'Brien filed Form 4 for Provention Bio, Inc. on 11 Jan 2023.
Change
- Previous filing in this sequence was filed on 19 Sep 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PRVB
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +8,000
- Change %
- +8%
- Price
- $0.000000
- Shares after
- 108,000
- Date
- 10 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.0001
- Underlying amount
- 8,000
- Exercise price
- $5.35
- Footnotes
- F1, F2
PRVB
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +100,000
- Change %
- Price
- $0.000000
- Shares after
- 100,000
- Date
- 10 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.0001
- Underlying amount
- 100,000
- Exercise price
- $8.93
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
As previously reported on a Form 4 filed on September 19, 2022, on September 15, 2022, the Reporting Person was granted a stock option for 200,000 shares of Common Stock, 100,000 of which option shares vest in four equal annual installments commencing on September 15, 2023 and 100,000 of which option shares vest upon completion of certain performance milestones. This amount represents the vesting of 8,000 of the 100,000 performance options shares on January 10, 2023 upon the satisfaction of certain performance milestones.
Footnote F2
The stock options were granted pursuant to the Issuer's 2020 Inducement Plan, as amended.
Footnote F3
The options will vest and become exercisable as to 25% on the one-year anniversary of the grant date (January 10, 2024) and the remaining 75% will vest and become exercisable monthly over 36 months such that the options are fully vested and exercisable on the four-year anniversary of the grant date (January 10, 2027).
Footnote F4
The securities were granted pursuant to the Issuer's Amended and Restated 2017 Equity Incentive Plan.